New Delhi, March 25 -- The anti-malarial drug hydroxychloroquine has been approved by the national task force of the Indian Council of Medical Research (ICMR) as a prophylaxis - treatment to prevent disease - for people at high risk of contracting Covid-19, according to the Union ministry of health.

High-risk population has been defined as health care workers involved in taking care of or treatment of suspected and confirmed patients of the coronavirus disease and asymptomatic people living in the same house as a laboratory-confirmed Covid-19 case.

India's drug regulator - Drug Controller General of India - has approved restricted use of the medicine in emergency.

So far, there is no conclusive proof of the medicine working against Covid...